Benralizumab

Red

Brand Name(s):Fasenra

Indication:severe eosinophilic asthma

Rationale:1,2,8

Considered:Sep-19

Review Date:Sep-24

Comments:
…………………………NICE TA565 ………………………… .Benralizumab is an anti-eosinophil, humanised afucosylated, monoclonal antibody licensed as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting ?-agonists.